‹ ›
MYP_110330
← PREVIOUS NEXT → BACK
Basic Information
LP-55
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
26 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
WEQKIEELLKKAEEQQKKNEEELKKX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0003932 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 25 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antimicrobial Antiviral
T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells
0.00001 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0027779 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 26
Bio-Activity Profile
Antiviral
HIV-2
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0045598 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 25 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
T-20 resistant HIV-1 NL4-3 (WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T) | TZM-bl cells
0.00011-0.18934 μM
IC50
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0046078 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 25 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells
0.000014±0.000002 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0055824 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 25 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 | TZM-bl cells
0.000008±0.000001 μM
IC50
Mammalian: 2.8 h; Yeast: 3 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
1 2 3 ... 6 NEXT LAST
Showing 5 records on this page · Page 1 of 6